Podlesak Dennis 4
4 · Syndax Pharmaceuticals Inc · Filed Sep 16, 2022
Insider Transaction Report
Form 4
Podlesak Dennis
Director
Transactions
- Exercise/Conversion
Stock Options (Right to buy)
2022-09-16−6,556→ 0 totalExercise: $6.35Exp: 2024-12-18→ Common Stock (6,556 underlying) - Exercise/Conversion
Common Stock
2022-09-15$6.32/sh+66,840$422,429→ 142,603 total - Sale
Common Stock
2022-09-15$24.20/sh−66,840$1,617,381→ 75,763 total - Exercise/Conversion
Common Stock
2022-09-16$6.35/sh+6,556$41,631→ 82,319 total - Exercise/Conversion
Common Stock
2022-09-16$6.32/sh+5,419$34,248→ 81,182 total - Sale
Common Stock
2022-09-16$23.43/sh−5,419$126,982→ 75,763 total - Sale
Common Stock
2022-09-16$23.43/sh−6,556$153,625→ 75,763 total - Exercise/Conversion
Stock Options (Right to buy)
2022-09-15−66,840→ 0 totalExercise: $6.32Exp: 2024-09-15→ Common Stock (66,840 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2022-09-16−5,419→ 0 totalExercise: $6.32Exp: 2024-09-15→ Common Stock (5,419 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 192,600 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.
- [F2]The sale prices ranged from $23.37 to $24.64
- [F3]The sale prices ranged from $22.96 to $24.07
- [F4]This option is fully vested.